NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that it is expected to join the Russell Microcap Index as part of FTSE Russell's first semi-annual 2026 reconstitution. The inclusion, based on preliminary lists published on May 22, May 29, and June 5, 2026, will take effect after the U.S. market close on June 26, 2026.
This development marks a significant milestone for the medical technology company, which focuses on surgical solutions for neurological disorders. CEO Dave Rosa stated, "We believe our inclusion reflects the commercial momentum we have built across our portfolio of FDA-cleared electrode and ablation technologies, and the increasing recognition of NeuroOne within the investment community. We expect membership in the index to expand our visibility among institutional investors and broaden our shareholder base as we continue our mission of transforming the treatment of neurological disorders."
The Russell Microcap Index is part of the broader Russell US Indexes, which are widely used by institutional investors for benchmarking and passive investment strategies. Inclusion in the index typically leads to increased demand for a company's stock from index funds and exchange-traded funds that track the index, potentially boosting liquidity and shareholder diversity.
NeuroOne markets four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. These technologies aim to improve surgical outcomes and reduce costs by offering diagnostic and therapeutic functions. The company also engages in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
The shift from an annual to a semi-annual reconstitution schedule by FTSE Russell, beginning in 2026, provides more frequent opportunities for companies like NeuroOne to be added to the indexes. This change reflects the evolving nature of the small-cap market and allows for timelier adjustments based on company growth.
For NeuroOne, index membership could attract institutional investors that previously may have overlooked the stock due to its smaller market capitalization. This broader investor base can provide more stable long-term support and potentially reduce stock price volatility. As the company continues to develop its technologies and pursue new indications, access to capital and investor confidence are critical.
The company's forward-looking statements caution that actual results may differ materially due to risks such as supply chain disruptions, regulatory changes, and market acceptance of its technology. However, the preliminary inclusion in the Russell Microcap Index signals confidence in NeuroOne's trajectory.
More information about NeuroOne is available at nmtc1.com.
